Concord Drugs Overview
- Year Founded
-
1995
- Status
-
Public
- Employees
-
250
- Stock Symbol
-
538965
- Investments
-
1
- Share Price
-
$0.76
- (As of Friday Closing)
Concord Drugs General Information
Description
Concord Drugs Ltd is an India-based pharmaceutical company. The principal activity of the company is to manufacture licensed drugs based on approved formulations. Its product portfolio includes Pharmaceutical Ready-to-fill Pellets, MUPS (Multiple Unit Pellets System); Tissue Bio Adhesive; Injectables (Small Volume Parenterals); Capsules; Liquid Orals (Syrups & Suspensions); Dry Syrups (Powder); and Hand Sanitizers, among others.
Contact Information
Website
www.concorddrugs.inCorporate Office
- Survey Number 249, Brahmanapally Village
- Hayathnagar Mandal, Ranga Reddy District
- Hyderabad, Telangana 501511
- India
Corporate Office
- Survey Number 249, Brahmanapally Village
- Hayathnagar Mandal, Ranga Reddy District
- Hyderabad, Telangana 501511
- India
Concord Drugs Stock Performance
As of 13-Nov-2026, Concord Drugs’s stock price is $0.76. Its current market cap is $10M with 13.2M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.76 | $0.78 | $0.63 - $1.02 | $10M | 13.2M | 4.42K | $0.02 |
Concord Drugs Financials Summary
As of 30-Jun-2026, Concord Drugs has a trailing 12-month revenue of $9.5M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2026 31-Mar-2026 | FY 2025 31-Mar-2025 | FY 2024 31-Mar-2024 |
|---|---|---|---|---|
| EV | 12,265 | 11,514 | 5,820 | 6,223 |
| Revenue | 9,498 | 8,911 | 5,351 | 5,427 |
| EBITDA | 643 | 504 | 485 | 488 |
| Net Income | 226 | 119 | 40 | 57 |
| Total Assets | 7,937 | 7,615 | 7,052 | |
| Total Debt | 0 | 1,538 | 2,250 | 2,101 |
Concord Drugs Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Concord Drugs Comparisons
Industry
Financing
Details
Concord Drugs Competitors (3)
One of Concord Drugs’s 3 competitors is Cipla, a Corporation company based in Mumbai, India.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Cipla | Corporation | Mumbai, India | ||||
| Novartis | Corporation | Basel, Switzerland | ||||
| Torrent Pharmaceuticals | Corporation | Ahmedabad, India |
Concord Drugs Signals
Concord Drugs Acquisitions (1)
Concord Drugs’s most recent deal was a Merger/Acquisition with Proton Remedies. The deal was made on 08-Sep-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Proton Remedies | 08-Sep-2022 | Merger/Acquisition | Multi-line Chemicals |
Concord Drugs ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
Concord Drugs FAQs
-
When was Concord Drugs founded?
Concord Drugs was founded in 1995.
-
Where is Concord Drugs headquartered?
Concord Drugs is headquartered in Hyderabad, India.
-
What is the size of Concord Drugs?
Concord Drugs has 250 total employees.
-
What industry is Concord Drugs in?
Concord Drugs’s primary industry is Drug Discovery.
-
Is Concord Drugs a private or public company?
Concord Drugs is a Public company.
-
What is Concord Drugs’s stock symbol?
The ticker symbol for Concord Drugs is 538965.
-
What is the current stock price of Concord Drugs?
As of 13-Nov-2026 the stock price of Concord Drugs is $0.76.
-
What is the current market cap of Concord Drugs?
The current market capitalization of Concord Drugs is $10M.
-
What is Concord Drugs’s current revenue?
The trailing twelve month revenue for Concord Drugs is $9.5M.
-
Who are Concord Drugs’s competitors?
Cipla, Novartis, and Torrent Pharmaceuticals are competitors of Concord Drugs.
-
What is Concord Drugs’s annual earnings per share (EPS)?
Concord Drugs’s EPS for 12 months was $0.02.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process